A guide for US sponsors: what a defensible European cardiovascular study depends on, from investigator and imaging infrastructure to endpoints, adjudication, and the intended FDA and EU MDR uses of the data.
Expert reviewed by
COO & Head of Cardiovascular
Consultant Cardiac Surgeon, 25 years of practice, with senior clinical review experience inside a European Notified Body.
Publication
Platinum Award, xShare Clinical Research Open Call 2026
Eclevar MedTech and MILO received the Platinum Award through the xShare Clinical Research Open Call, organized by EUCROF and co-funded by the European Union.
Europe can provide relevant investigators, sites, imaging infrastructure, and patient populations for cardiovascular device development. Whether it should host your study is a separate question: a defensible European cardiovascular study depends on procedure-specific expertise, population applicability, imaging quality, operator learning, event definitions, safety escalation, and the intended FDA and EU evidence uses. Europe is a candidate geography, to be assessed against your device, your procedure, and your regulatory plan.
None of these is a default. The right model is a function of the device, the procedure, and the intended regulatory use, not a geographic preference; Eclevar designs both Europe-led and hybrid cardiovascular studies and integrates either with the sponsor's intended FDA pathway.
European sites can host most stages of cardiovascular clinical development. Fit depends on device maturity, the decision the study must inform, and where the evidence will be used; a further feasibility step, or US-style early feasibility design, is one of these stages, not a separate track.
This is not a mandatory sequence: a program may enter at pivotal or post-market stage, and not every device passes through all four. Early clinical use, including US-style early feasibility designs, is covered in our guide to early feasibility studies.
Who makes up the treating heart team?
And who actually decides that a patient is treated.
What procedure volume is relevant?
Count the specific procedure and access route, not the broad category.
Which imaging modalities are required?
At baseline, during the procedure, and at follow-up.
Is surgical or emergency backup available?
Physically available when the procedure is performed.
How mature are the device and procedure?
And what that implies for training and oversight.
What operator-learning effect is expected?
And how it will be documented across the case sequence.
Which endpoints drive the next decision?
And can these sites measure them consistently.
Is independent adjudication needed?
For the events that matter to the claim.
Can the site complete long-term follow-up?
Including patients who return to distant referral centers.
Does local practice reflect the intended US use?
Closely enough for the data to transfer; one of the questions FDA may consider when assessing applicability.
A prominent KOL is not automatically the best principal investigator, nor a famous center the best site. Every investigational procedure sits inside a system of clinical functions; if any one is weak, the study inherits that weakness.
Conceptual framework. Site qualification assesses each function against the protocol; no scoring system is implied, and observed outcomes may reflect several of these functions together.
The Cardiovascular Site Is a Clinical System
Six site functions that surround every investigational cardiovascular procedure.
Selection covers exact procedural experience with the access route the protocol requires, comparable-technology experience, and research discipline, including willingness to report device problems. Early cases typically run longer, with more variable preparation; if this is not planned for, early complications can be misread as device failures.
In most cardiovascular device studies, imaging is the endpoint, or at least the mechanism behind it, which makes it a quality system that has to be designed, not assumed. Sites that treat research imaging as an extension of clinical routine produce datasets with holes exactly where the regulatory questions are.
A Clinical Events Committee may be appropriate when endpoint or safety events require independent, standardized classification; the decision depends on endpoint complexity, study risk, and the value of independent adjudication. A Data Safety Monitoring Board adds value where enrollment continues while risk is still being characterized.
Cardiovascular data architecture has requirements generic EDC builds miss: device traceability down to size and configuration, time-point control across countries, and imaging integrated with the clinical database rather than living beside it. Statistically, the plan should anticipate missing follow-up and address competing risks where mortality competes with the endpoint of interest.
Cardiovascular evidence spans initial safety, device and procedural success, technical performance, clinical effectiveness, functional status, quality of life, reintervention, mortality, and long-term durability. A study rarely needs all of these as formal endpoints; it needs the ones that drive the next decision, defined precisely, timed correctly, and adjudicated where the events are consequential. Where consensus definitions exist, use them and name them: VARC-3 for TAVR, and MVARC and TVARC for transcatheter mitral and tricuspid interventions.
Swipe sideways to view all columns.
| Endpoint domain | Early study role | Pivotal role | Key control |
|---|---|---|---|
| Technical success | Device functionality | Supportive or component endpoint | Precise procedural definition |
| Procedural success | Early feasibility and safety | May inform composite outcomes | Adjudication and time point |
| Safety events | Initial event characterization | Prespecified safety analysis | Standardized definitions |
| Imaging | Mechanism and performance | Objective performance assessment | Core-lab or controlled reading |
| Clinical outcomes | Exploratory signal | Confirmatory evidence | Follow-up and statistical plan |
| Patient-reported outcomes | Burden and functional change | Claim-supporting where appropriate | Validated instrument and timing |
Cardiovascular evidence is assembled in stages, and each stage draws on specific data sources. Designing the study means designing this pipeline before the first patient is treated.
| Dimension | Europe-led | Hybrid US-Europe |
|---|---|---|
| Investigator / site access | Established European procedural expertise for the technique | Selected US sites added where US practice must be demonstrated inside the study |
| Population & standard of care | Access to the intended patient population in Europe | Applicability to US practice patterns tested directly |
| FDA & commercial market | Serves a European market objective with the same evidence | FDA feedback, comparator availability, or launch-readiness argue for US sites |
When a US-led study may remain appropriate: when the intended use, comparator technology, and practice pattern are distinctly American, a US-only program may serve the evidence question better than either European option. Eclevar designs both Europe-led and hybrid cardiovascular studies and integrates either model with the sponsor's intended FDA pathway.
Meril Life SciencesMulticenter transcatheter heart valve program with Meril Life Sciences. Eclevar delivers a multicenter transcatheter aortic valve implantation clinical program in the United Kingdom, with an evidence design aligned with the requirements of UK health technology assessment.
Eclevar's contribution:
This program is not a US IDE or FDA pivotal study, and no clinical results or regulatory outcomes are reported here. It is presented, without sponsor endorsement, as evidence of Eclevar's cardiovascular procedural study delivery in Europe.
The sponsor name and logo are shown solely to identify the program described. Their display does not imply endorsement of Eclevar MedTech.
25 years · Consultant Cardiac Surgery
Dr Mark Da Costa, COO & Head of Cardiovascular, combines practicing cardiovascular judgment with first-hand senior leadership experience inside a European Notified Body.
Around that physician leadership, cardiovascular programs are delivered by named functional leads:
Former positions are stated for biographical context only. Eclevar MedTech is independent of, and not endorsed by, any Notified Body. Eclevar's European team works with Dawn Heimer's US clinical and FDA-interaction experience to keep European study design aligned with the sponsor's intended FDA pathway, while overall US regulatory strategy remains with the sponsor and its US advisors.
The Study Strategy Review provides a documented assessment of the clinical, operational, and regulatory decisions shaping your European program.
Official content
Whitepapers, client voices and publications produced by our own teams and by our partners: BSI, TÜV SÜD and RegenLab.
Whitepaper · BSI x Eclevar
Written with the notified body BSI: a practical look at what clinical evidence has to show under EU MDR 2017/745, and at the quality bar the data have to clear. It is the same bar a European dataset meets before it is put in front of any reviewer.
PMCF studies · Regenerative medicine · 5 EU countries
Eclevar runs RegenLab's PMCF program on chronic wound products. It is a randomized study of 160 subjects across 14 centers in 5 EU countries, covering both diabetic foot ulcer and venous leg ulcer. The partnership combines Eclevar's ISO 14155 expertise with the Milo Studio platform, from study design through to the final study report.
« Eclevar, with its tailored approach and the advanced Milo Studio platform, represents a significant strategic advantage. »Antoine Turzi, CEO, RegenLab
Coming soon. Breakthrough Device Technology under the EU MDR, a whitepaper written with TÜV SÜD, co-authored by Dr Nikhil Khadabadi.
Yes, where preclinical evidence supports the intended stage and a competent authority and ethics committee approve the investigation under EU MDR. The deciding factors are procedure-specific operator expertise, safety infrastructure, and imaging capability at the selected sites, not geography as such.
European clinical data may support an FDA submission when the study is designed, conducted, and documented for its intended regulatory use; final acceptability remains subject to FDA review. The governing provisions include 21 CFR 812.28 and, for applications based solely on foreign data, 21 CFR 814.15. Conformity with ISO 14155:2026 does not by itself establish FDA acceptability.
When population applicability, US practice patterns, FDA feedback, or launch-readiness argue for US sites, while European sites contribute expertise, patients, or a European market objective.
Against the protocol, not against reputation: exact procedural experience, case volume, imaging quality, heart-team function, surgical backup, follow-up capability, and demonstrated research discipline.
Device and intended use, the procedure, development stage, existing evidence, proposed endpoints, imaging requirements, investigator relationships, intended FDA and European pathways, and the target timeline. That is the input set of the Study Strategy Review.
Yes. Eclevar delivers imaging workflows and core-lab coordination, monitoring, data management, biostatistics, safety and adjudication support, and clinical investigation reporting, with submissions to authorities and ethics committees prepared in-house.
